---
document_datetime: 2025-12-02 05:34:30
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ztalmy.html
document_name: ztalmy.html
version: success
processing_time: 0.1117045
conversion_datetime: 2025-12-26 18:12:20.720078
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ztalmy

[RSS](/en/individual-human-medicine.xml/67687)

##### Authorised

This medicine is authorised for use in the European Union

ganaxolone Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ztalmy](#news-on)
- [More information on Ztalmy](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ztalmy is a medicine used to treat epileptic seizures in children from 2 to 17 years of age who have a condition known as cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. These patients can continue taking Ztalmy when they become adults if a clear benefit has been observed.

The medicine is used in combination with other anti-epileptic medicines.

CDKL5 deficiency disorder is rare, and Ztalmy was designated an 'orphan medicine' (a medicine used in rare diseases) on 13 November 2019. Further information on the orphan designation can be found on the EMA [website](/en/medicines/human/orphan-designations/eu-3-19-2224) .

Ztalmy contains the active substance ganaxolone.

Expand section

Collapse section

## How is Ztalmy used?

The medicine can only be obtained with a prescription, and treatment should be started and supervised by a doctor who has experience in treating patients with epilepsy.

Ztalmy is available as a liquid to be taken by mouth and is usually given three times a day. The dose is determined by the patient's weight.

For more information about using Ztalmy, see the package leaflet or contact your doctor or pharmacist.

## How does Ztalmy work?

The active substance in Ztalmy, ganaxolone, mimics the action of a substance in the body called allopregnanolone. It switches on so-called GABA receptors, which reduces excessive electrical activity in the brain and thus lowers the number of seizures.

## What benefits of Ztalmy have been shown in studies?

A main study showed that Ztalmy reduces the frequency of seizures in children and adolescents with CDKL5 deficiency disorder who are taking at least one other epilepsy medicine.

The study involved a total of 101 patients with CDKL5 deficiency disorder and compared Ztalmy with placebo (a dummy treatment), both given in addition to existing epilepsy medicines.

On average, the monthly number of major seizures was reduced by 29% in the group of patients treated with Ztalmy, and by 6% in the group treated with placebo.

## What are the risks associated with Ztalmy?

For the full list of side effects and restrictions with Ztalmy, see the package leaflet.

The most common side effects with Ztalmy (which may affect more than 1 in 10 people) include sleepiness and fever.

## Why is Ztalmy authorised in the EU?

The main study showed that Ztalmy is effective at reducing the number of seizures in children with CDKL5 deficiency disorder. The side effects are considered manageable. The European Medicines Agency therefore decided that Ztalmy's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ztalmy?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ztalmy have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ztalmy are continuously monitored. Suspected side effects reported with Ztalmy are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ztalmy

Ztalmy received a marketing authorisation valid throughout the EU on 26 July 2023.

Ztalmy : EPAR - Medicine Overview

Reference Number: EMA/314982/2023

English (EN) (103.91 KB - PDF)

**First published:** 31/07/2023

[View](/en/documents/overview/ztalmy-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-801)

български (BG) (142.15 KB - PDF)

**First published:**

31/07/2023

[View](/bg/documents/overview/ztalmy-epar-medicine-overview_bg.pdf)

español (ES) (119.34 KB - PDF)

**First published:**

31/07/2023

[View](/es/documents/overview/ztalmy-epar-medicine-overview_es.pdf)

čeština (CS) (140.69 KB - PDF)

**First published:**

31/07/2023

[View](/cs/documents/overview/ztalmy-epar-medicine-overview_cs.pdf)

dansk (DA) (118.5 KB - PDF)

**First published:**

31/07/2023

[View](/da/documents/overview/ztalmy-epar-medicine-overview_da.pdf)

Deutsch (DE) (121.03 KB - PDF)

**First published:**

31/07/2023

[View](/de/documents/overview/ztalmy-epar-medicine-overview_de.pdf)

eesti keel (ET) (117.01 KB - PDF)

**First published:**

31/07/2023

[View](/et/documents/overview/ztalmy-epar-medicine-overview_et.pdf)

ελληνικά (EL) (141.28 KB - PDF)

**First published:**

31/07/2023

[View](/el/documents/overview/ztalmy-epar-medicine-overview_el.pdf)

français (FR) (119.6 KB - PDF)

**First published:**

31/07/2023

[View](/fr/documents/overview/ztalmy-epar-medicine-overview_fr.pdf)

hrvatski (HR) (141.93 KB - PDF)

**First published:**

31/07/2023

[View](/hr/documents/overview/ztalmy-epar-medicine-overview_hr.pdf)

italiano (IT) (118.86 KB - PDF)

**First published:**

31/07/2023

[View](/it/documents/overview/ztalmy-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (147.74 KB - PDF)

**First published:**

31/07/2023

[View](/lv/documents/overview/ztalmy-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (138.88 KB - PDF)

**First published:**

31/07/2023

[View](/lt/documents/overview/ztalmy-epar-medicine-overview_lt.pdf)

magyar (HU) (138.78 KB - PDF)

**First published:**

31/07/2023

[View](/hu/documents/overview/ztalmy-epar-medicine-overview_hu.pdf)

Malti (MT) (142.39 KB - PDF)

**First published:**

31/07/2023

[View](/mt/documents/overview/ztalmy-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.87 KB - PDF)

**First published:**

31/07/2023

[View](/nl/documents/overview/ztalmy-epar-medicine-overview_nl.pdf)

polski (PL) (143.21 KB - PDF)

**First published:**

31/07/2023

[View](/pl/documents/overview/ztalmy-epar-medicine-overview_pl.pdf)

português (PT) (120.31 KB - PDF)

**First published:**

31/07/2023

[View](/pt/documents/overview/ztalmy-epar-medicine-overview_pt.pdf)

română (RO) (137.44 KB - PDF)

**First published:**

31/07/2023

[View](/ro/documents/overview/ztalmy-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.54 KB - PDF)

**First published:**

31/07/2023

[View](/sk/documents/overview/ztalmy-epar-medicine-overview_sk.pdf)

slovenščina (SL) (137.42 KB - PDF)

**First published:**

31/07/2023

[View](/sl/documents/overview/ztalmy-epar-medicine-overview_sl.pdf)

Suomi (FI) (116.58 KB - PDF)

**First published:**

31/07/2023

[View](/fi/documents/overview/ztalmy-epar-medicine-overview_fi.pdf)

svenska (SV) (117.42 KB - PDF)

**First published:**

31/07/2023

[View](/sv/documents/overview/ztalmy-epar-medicine-overview_sv.pdf)

Ztalmy : EPAR - Risk management plan

English (EN) (1014.61 KB - PDF)

**First published:** 31/07/2023

**Last updated:** 02/06/2025

[View](/en/documents/rmp-summary/ztalmy-epar-risk-management-plan_en.pdf)

## Product information

Ztalmy : EPAR - Product Information

English (EN) (740.48 KB - PDF)

**First published:** 31/07/2023

**Last updated:** 18/07/2025

[View](/en/documents/product-information/ztalmy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-549)

български (BG) (814.95 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/bg/documents/product-information/ztalmy-epar-product-information_bg.pdf)

español (ES) (741.92 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/es/documents/product-information/ztalmy-epar-product-information_es.pdf)

čeština (CS) (800.42 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/cs/documents/product-information/ztalmy-epar-product-information_cs.pdf)

dansk (DA) (733.34 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/da/documents/product-information/ztalmy-epar-product-information_da.pdf)

Deutsch (DE) (762.07 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/de/documents/product-information/ztalmy-epar-product-information_de.pdf)

eesti keel (ET) (732.45 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/et/documents/product-information/ztalmy-epar-product-information_et.pdf)

ελληνικά (EL) (799.03 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/el/documents/product-information/ztalmy-epar-product-information_el.pdf)

français (FR) (793.21 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/fr/documents/product-information/ztalmy-epar-product-information_fr.pdf)

hrvatski (HR) (824.33 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/hr/documents/product-information/ztalmy-epar-product-information_hr.pdf)

íslenska (IS) (707.79 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/is/documents/product-information/ztalmy-epar-product-information_is.pdf)

italiano (IT) (764.44 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/it/documents/product-information/ztalmy-epar-product-information_it.pdf)

latviešu valoda (LV) (771.32 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/lv/documents/product-information/ztalmy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (804.91 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/lt/documents/product-information/ztalmy-epar-product-information_lt.pdf)

magyar (HU) (799.98 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/hu/documents/product-information/ztalmy-epar-product-information_hu.pdf)

Malti (MT) (831.08 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/mt/documents/product-information/ztalmy-epar-product-information_mt.pdf)

Nederlands (NL) (799.7 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/nl/documents/product-information/ztalmy-epar-product-information_nl.pdf)

norsk (NO) (735.83 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/no/documents/product-information/ztalmy-epar-product-information_no.pdf)

polski (PL) (799.28 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/pl/documents/product-information/ztalmy-epar-product-information_pl.pdf)

português (PT) (756.38 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/pt/documents/product-information/ztalmy-epar-product-information_pt.pdf)

română (RO) (806.73 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/ro/documents/product-information/ztalmy-epar-product-information_ro.pdf)

slovenčina (SK) (844.03 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/sk/documents/product-information/ztalmy-epar-product-information_sk.pdf)

slovenščina (SL) (785.15 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/sl/documents/product-information/ztalmy-epar-product-information_sl.pdf)

Suomi (FI) (732.41 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/fi/documents/product-information/ztalmy-epar-product-information_fi.pdf)

svenska (SV) (766.85 KB - PDF)

**First published:**

31/07/2023

**Last updated:**

18/07/2025

[View](/sv/documents/product-information/ztalmy-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000281558 18/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ztalmy : EPAR - All authorised presentations

English (EN) (44.52 KB - PDF)

**First published:** 31/07/2023

[View](/en/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-674)

български (BG) (67.15 KB - PDF)

**First published:**

31/07/2023

[View](/bg/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_bg.pdf)

español (ES) (49.94 KB - PDF)

**First published:**

31/07/2023

[View](/es/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (68.3 KB - PDF)

**First published:**

31/07/2023

[View](/cs/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (50.85 KB - PDF)

**First published:**

31/07/2023

[View](/da/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.86 KB - PDF)

**First published:**

31/07/2023

[View](/de/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (48.63 KB - PDF)

**First published:**

31/07/2023

[View](/et/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (66.92 KB - PDF)

**First published:**

31/07/2023

[View](/el/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_el.pdf)

français (FR) (49.66 KB - PDF)

**First published:**

31/07/2023

[View](/fr/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (70.02 KB - PDF)

**First published:**

31/07/2023

[View](/hr/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (46.25 KB - PDF)

**First published:**

31/07/2023

[View](/is/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (48.79 KB - PDF)

**First published:**

31/07/2023

[View](/it/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.1 KB - PDF)

**First published:**

31/07/2023

[View](/lv/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.97 KB - PDF)

**First published:**

31/07/2023

[View](/lt/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (67.37 KB - PDF)

**First published:**

31/07/2023

[View](/hu/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (71.75 KB - PDF)

**First published:**

31/07/2023

[View](/mt/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (49.22 KB - PDF)

**First published:**

31/07/2023

[View](/nl/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (46.14 KB - PDF)

**First published:**

31/07/2023

[View](/no/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_no.pdf)

polski (PL) (72.32 KB - PDF)

**First published:**

31/07/2023

[View](/pl/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_pl.pdf)

português (PT) (49.73 KB - PDF)

**First published:**

31/07/2023

[View](/pt/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_pt.pdf)

română (RO) (65.17 KB - PDF)

**First published:**

31/07/2023

[View](/ro/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (70.22 KB - PDF)

**First published:**

31/07/2023

[View](/sk/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (57.37 KB - PDF)

**First published:**

31/07/2023

[View](/sl/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (48.45 KB - PDF)

**First published:**

31/07/2023

[View](/fi/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.97 KB - PDF)

**First published:**

31/07/2023

[View](/sv/documents/all-authorised-presentations/ztalmy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ztalmy Active substance ganaxolone International non-proprietary name (INN) or common name ganaxolone Therapeutic area (MeSH)

- Epileptic Syndromes
- Spasms, Infantile

Anatomical therapeutic chemical (ATC) code N03AX

### Pharmacotherapeutic group

Other antiepileptics

### Therapeutic indication

Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older.

## Authorisation details

EMA product number EMEA/H/C/005825

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Marinus Pharmaceuticals Emerald Limited

10 Earlsfort Terrace

Opinion adopted 25/05/2023 Marketing authorisation issued 26/07/2023 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ztalmy : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (128.03 KB - PDF)

**First published:** 02/06/2025

**Last updated:** 18/07/2025

[View](/en/documents/procedural-steps-after/ztalmy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ztalmy : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (152.67 KB - PDF)

**First published:** 11/07/2024

**Last updated:** 02/06/2025

[View](/en/documents/procedural-steps-after/ztalmy-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Ztalmy : EPAR - Orphan Maintenance Assessment Report

Adopted

Reference Number: EMA/OD/0000071368

English (EN) (369.04 KB - PDF)

**First published:** 31/07/2023

[View](/en/documents/orphan-maintenance-report/ztalmy-epar-orphan-maintenance-assessment-report_en.pdf)

Ztalmy : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/267469/2023

English (EN) (2.65 MB - PDF)

**First published:** 31/07/2023

[View](/en/documents/assessment-report/ztalmy-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ztalmy

Adopted

Reference Number: EMA/CHMP/207481/2023

English (EN) (128.64 KB - PDF)

**First published:** 26/05/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ztalmy_en.pdf)

#### News on Ztalmy

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 May 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-may-2023) 26/05/2023

#### More information on Ztalmy

- [EU/3/19/2224 - orphan designation for treatment of CDKL5 deficiency disorder](/en/medicines/human/orphan-designations/eu-3-19-2224)
- [EMEA-002341-PIP01-18-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002341-pip01-18-m03)
- [EMEA-002341-PIP02-23 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002341-pip02-23)

**This page was last updated on** 18/07/2025

## Share this page

[Back to top](#main-content)